Tag

multiple myeloma; blood cancer
Myeloma New Zealand has started a campaign to press Pharmac into funding a treatment that has been standard-of-care throughout the Organisation for Economic Co-operation and Development (OECD) for more than five years. Myeloma NZ trustee Nichola Oakenfull has been interviewed for the article, well done Nichola! Here is the RNZ article: https://www.rnz.co.nz/news/national/474629/blood-cancer-patient-charity-campaigns-for-pharmac-to-fund-medicine
Continue Reading
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major, evidence-based campaign to press Pharmac into funding a transformative treatment that has been standard-of-care throughout the OECD for more than 5 years.    Myeloma patient and trustee of Myeloma NZ Nichola Oakenfull says patients who’ve...
Continue Reading
As we continue to understand more about the biology of multiple myeloma (MM) and the number of treatment options for patients with MM continues to expand, keeping track of the current standard of care practices and emerging new treatment strategies has become even more challenging. In this commentary, we will summarize our thoughts on how...
Continue Reading
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit is a welcome way of drawing attention to the plight of NZ cancer patients desperate for treatments that are funded across the Tasman, but not here, says Myeloma NZ Chief Executive Dr Ken...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand